quinazolines has been researched along with Adenoma, beta-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergmann, F; Breinig, M; Ehemann, V; Esposito, I; Fischer, L; Friess, H; Herpel, E; Höpfner, M; Kern, MA; Kleeff, J; Köhler, C; Rieker, RJ; Schirmacher, P | 1 |
| Gerst, B; Höpfner, M; Scherübl, H; Sutter, AP; Zeitz, M | 1 |
2 other study(ies) available for quinazolines and Adenoma, beta-Cell
| Article | Year |
|---|---|
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Blotting, Western; Carcinoid Tumor; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Insulinoma; Male; Mice; Mice, Transgenic; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tyrphostins; Young Adult | 2009 |
A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839).
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Fluorescent Antibody Technique; Gastrointestinal Neoplasms; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulinoma; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2003 |